Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy

Current Oncology

Volumn 21, Issue 2, 2014, Pages

  Klein, J ^a   Dawson, L A ^a   Tran, T H ^a   Adeyi, O ^b   Purdie, T ^a   Sherman, M ^c   Brade, A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Hepatocellular carcinoma; IMRT; Liver cancer; Metabolic syndrome; Radiotherapy; SBRT; VMAT

Indexed keywords

ALPHA FETOPROTEIN;

AGED; ARTICLE; BIOPSY; CASE REPORT; CHEMOEMBOLIZATION; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIATION DOSE; SLEEP DISORDERED BREATHING; STEATOSIS; SURVIVAL; VOLUMETRIC MODULATED ARC THERAPY;

EID: 84898778077     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1756     Document Type: Article

References (25)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
3. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010;59:1303-7.
4. Grundy SM, Cleeman JI, Daniels SR, et al. on behalf of the American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52. [Erratum in: Circulation 2005;112:e297-8]
5. Valle JW, Dangoor A, Beech J, et al. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (pld): results of a phase ii study. Br J Cancer 2005;92:628-30.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
7. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase iii randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
8. Bujold A, Massey CA, Kim JJ, et al. Sequential phase i and ii trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.
9. Letourneau D, Wong JW, Oldham M, et al. Cone-beam-ct guided radiation therapy: technical implementation. Radiother Oncol 2005;75:279-86.
10. Eccles CL, Patel R, Simeonov AK, Lockwood G, Haider M, Dawson LA. Comparison of liver tumor motion with and without abdominal compression using cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2011;79:602-8.
11. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012;10:1342-59.e2.
12. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58.
13. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the seer-Medicare database. Hepatology 2011;54:463-71.
14. Turati F, Talamini R, Pelucchi C, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013;108:222-8.
15. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80.
16. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007;97:1005-8.
17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
18. Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012;43:737-46.
19. Paradis V, Albuquerque M, Mebarki M, et al. Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome. Gut 2013;62:911-19.
20. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-53.
21. Cardenes HR, Price TR, Perkins SM, et al. Phase i feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-25.
22. Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189-93.
23. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003.
24. Palma D, Vollans E, James K, et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:996-1001.
25. Bujold A, Massey CA, Kim JJ, et al. Sequential phase i and ii trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.